Hillhurst Biopharmaceuticals, Inc.
3 clinical trials · Sponsor
◉ Watch Hillhurst Biopharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease (NCT07005180) | Hillhurst Biopharmaceuticals, Inc. | 2026-06-30 |
| A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) (NCT06144749) | Hillhurst Biopharmaceuticals, Inc. | 2025-02-15 |
| A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers (NCT03926819) | Hillhurst Biopharmaceuticals, Inc. | 2022-07-25 |
Track Hillhurst Biopharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.